Company Profile
Atossa Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- ATOS
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
2.45 USD (0.00%)
Close
Last updated: October 6, 2026
41.8M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, ATOS was little changed and closed at $2.45. No new same-company headline was identified in the current news window.
Company overview
Breast Cancer Therapeutics Company
Atossa Therapeutics develops medicines for breast cancer treatment and prevention. Its principal program is built around an active tamoxifen metabolite intended to provide consistent drug exposure without relying on metabolic conversion.
Z-Endoxifen Lead Candidate
(Z)-endoxifen is a potent estrogen-receptor antagonist and the most active metabolite of tamoxifen. Direct oral administration is intended to avoid variability caused by differences in CYP2D6 metabolism and concomitant medicines.
EVANGELINE Neoadjuvant Study
The Phase 2 EVANGELINE trial is evaluating (Z)-endoxifen with ovarian-function suppression before surgery in premenopausal women with ER-positive, HER2-negative breast cancer. The study assesses tumor response and biological activity in an earlier-stage treatment setting.
Endocrine-Resistance Opportunity
Preclinical work has shown estrogen-receptor inhibition across clinically relevant ESR1 mutations associated with resistance to endocrine therapy. This supports potential development in patients whose tumors progress after established hormonal treatments.
Broader Prevention and Combination Strategy
Atossa is also exploring (Z)-endoxifen in breast-cancer risk reduction, mammographic breast density, and combinations with other oncology agents. The company intends to use clinical data to guide partnering and later-stage development priorities.
Future catalysts
- Preliminary data from the Phase 2 EVANGELINE study in late 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Atossa Therapeutics, Inc. (ATOS)?
Atossa Therapeutics, Inc. (ATOS) most recently closed at 2.45 USD, a 0.00% move versus the previous session.
What is the market cap of Atossa Therapeutics, Inc. (ATOS)?
Atossa Therapeutics, Inc. currently has a market capitalization of 41.8M USD on BioPharmSignal.
What does Atossa Therapeutics, Inc. do?
Breast Cancer Therapeutics Company Atossa Therapeutics develops medicines for breast cancer treatment and prevention. Its principal program is built around an active tamoxifen metabolite intended to provide consistent drug exposure without relying on metabolic conversion. Z-Endoxifen Lead Candidate (Z)-endoxifen is a potent estrogen-receptor antagonist and...
On which exchange is ATOS stock listed?
Atossa Therapeutics, Inc. (ATOS) is associated with NASDAQ, United States, MedTech.
What is Breast?
Breast Cancer Therapeutics Company Atossa Therapeutics develops medicines for breast cancer treatment and prevention.
Which conditions is Atossa Therapeutics, Inc. targeting with Breast?
Atossa Therapeutics, Inc. is associated with oncology, cancer therapeutics, metabolic disease based on its company overview and current catalyst commentary.
How does Atossa Therapeutics, Inc. describe recent progress with Breast?
Preliminary data from the Phase 2 EVANGELINE study in late 2026.
What is Cancer?
Breast Cancer Therapeutics Company Atossa Therapeutics develops medicines for breast cancer treatment and prevention.